X

Trial Profile

Total XV - Total therapy study XV for newly diagnosed patients with acute lymphoblastic leukaemia.

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anthracyclines; Asparaginase; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Mercaptopurine; Methotrexate; Vincristine
Indications Precursor cell lymphoblastic leukaemia-lymphoma
Focus Biomarker; Pharmacogenomic; Therapeutic Use
Acronyms Total-XV

Most Recent Events

11 Sep 2020 Biomarkers information updated
25 Apr 2011 Planned end date changed from 1 Nov 2010 to 1 Nov 2020 as reported by ClinicalTrials.gov.
20 Dec 2010 Further results, from a subgroup of older adolescents, have been reported early online in the Clinical Journal of Oncology, according to a St Jude's media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com